Evidence map›Paper›PMID 31642140›Full record

ArticleThe journal of obstetrics and gynaecology research2020

Serous carcinoma of the uterine cervix: Clinicopathological features differing from serous carcinomas of other female organs.

Shoko Kitade, Kazuya Ariyoshi, Kenichi Taguchi, Shoji Maenohara, Yui Tomita, Kenzo Sonoda, Masao Okadome, Toshiaki Saito

Open access · hybridAbstract readEvaluation Study
In one paragraph

Article in The journal of obstetrics and gynaecology research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. The association between expression of p53 and aggressiveness of serous adenocarcinoma of the uterine cervix.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Shoko KitadeGynecology Service, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.ORCID https://orcid.org/0000-0001-7587-7112
Kazuya AriyoshiGynecology Service, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Kenichi TaguchiGynecology Service, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Shoji MaenoharaGynecology Service, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Yui TomitaGynecology Service, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Kenzo SonodaGynecology Service, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Masao OkadomeGynecology Service, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Toshiaki Saito
National Hospital Organization Kyushu Cancer Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimSerous carcinoma of the uterine cervix (USCC) is a very rare malignant tumor, while this histological subtype is common in the ovary, fallopian tube, uterine corpus and peritoneum. Because of its rarity, details of the clinicopathological features of USCC are largely unknown. We retrospectively analyzed the clinicopathological characteristics of five cases of pure USCC.

methodsWe reviewed the medical records and pathological specimens of five USCC cases who were treated at the Gynecology Service of the National Hospital Organization Kyushu Cancer Center, Japan, between 2000 and 2017. The clinicopathological features were also compared with those of serous carcinomas of the endometrium and ovary who were treated during the same period.

resultsFive patients were treated at our hospital between 2000 and 2017. Three tumors were stage IB1, one was stage IIB, and one was stage IVB. The median follow-up time was 104 months (range 26-210). Four patients other than stage IVB were treated with radical hysterectomy and have been free of relapse. One patient with stage IVB tumor was treated with platinum-based combination chemotherapy and is currently on maintenance therapy with bevacizumab and remains free of relapse.

conclusionUSCC has a distinctive clinicopathological feature that differentiates it from serous carcinomas of other female organs. USCC had been thought to be a poor prognostic disease; however, it could be curable if it is not accompanied by lymph node metastasis or peritoneal dissemination. We might conquer USCC even if it is accompanied by lymph node metastasis with the use of multimodal therapy.

Indexed as

AdultAgedCervix UteriCystadenocarcinoma, SerousFemaleGenital Neoplasms, FemaleHumansHysterectomyLymphatic MetastasisMiddle AgedNeoplasm StagingRetrospective StudiesTreatment OutcomeUterine Cervical Neoplasmscervical cancerpathologyprognostic factorserous carcinomatherapy

Identifiers

PMID31642140
PMCPMC7754289
OpenAlexW2981489013

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.